Zostavax: a subcutaneous vaccine for the prevention of herpes zoster

Bibliography

• LaRussa PS. Clinical manifestations of varicella. In: Arvin A, Gershon A, editors. Varicella-zoster virus. Cambridge University Press; Carmbridge, UK; 2000. p. 206-19
   Google Scholar
• Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am 1996;10(3):571-81
   PubMed Web of Science ®Google Scholar
• Weinberg JM. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol 2007;57(6 Suppl):S130-5
   PubMed Web of Science ®Google Scholar
• Weaver BA. Herpes zoster overview: natural history and incidence. J Am Osteopath Assoc 2009;109(6 Suppl 2):S2-6
   Google Scholar
• Takahashi M, Baba K, Horiuchi K, et al. A live varicella vaccine. Adv Exp Med Biol 1990;278:49-58
   PubMedGoogle Scholar
• Asano Y, Suga S, Yoshikawa T, et al. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994;94(4 Pt 1):524-6
   PubMed Web of Science ®Google Scholar
• Ellis RW. Varicella vaccine. Vaccine 1995;13(15):1387-8
   PubMed Web of Science ®Google Scholar
• Marin M, Guris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-4):1-40
   PubMedGoogle Scholar
• Russell AS, Maini RA, Bailey M, et al. Cell-mediated immunity to varicella-zoster antigen in acute herpes zoster (shingles). Clin Exp Immunol 1973;14(2):181-5
   PubMed Web of Science ®Google Scholar
• Jordan GW, Merigan TC. Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses. J Infect Dis 1974;130(5):495-501
   PubMed Web of Science ®Google Scholar
• Burke BL, Steele RW, Beard OW, et al. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982;142(2):291-3
   PubMed Web of Science ®Google Scholar
• Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol 2012;24(4):494-500
   PubMed Web of Science ®Google Scholar
• Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965;58:9-20
   PubMedGoogle Scholar
• Donahue JG, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med 1995;155(15):1605-9
   PubMed Web of Science ®Google Scholar
• Katz J, Cooper EM, Walther RR, et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004;39(3):342-8
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352(22):2271-84
   PubMed Web of Science ®Google Scholar
• Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005;20(8):748-53
   PubMed Web of Science ®Google Scholar
• Epstein E. Recurrences in herpes zoster. Cutis 1980;26(4):378-9
   PubMed Web of Science ®Google Scholar
• Helgason S, Sigurdsson JA, Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 1996;2(1):12-16
   Google Scholar
• Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996;67(2-3):241-51
   PubMed Web of Science ®Google Scholar
• Arani RB, Soong SJ, Weiss HL, et al. Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med 2001;20(16):2429-39
   PubMed Web of Science ®Google Scholar
• Jung BF, Johnson RW, Griffin DR, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004;62(9):1545-51
   PubMed Web of Science ®Google Scholar
• Lydick E, Epstein RS, Himmelberger D, et al. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995;45(12 Suppl 8):S52-3
   Web of Science ®Google Scholar
• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18(6):350-4
   PubMed Web of Science ®Google Scholar
• Tyring S, Belanger R, Bezwoda W, et al. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001;19(1):13-22
   PubMed Web of Science ®Google Scholar
• Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, et al. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000;342(9):635-45
   PubMed Web of Science ®Google Scholar
• Schmader K. Postherpetic neuralgia in immunocompetent elderly people. Vaccine 1998;16(18):1768-70
   PubMed Web of Science ®Google Scholar
• Schmader K. Herpes zoster in the elderly: issues related to geriatrics. Clin Infect Dis 1999;28(4):736-9
   PubMed Web of Science ®Google Scholar
• Watson P. Postherpetic neuralgia. Am Fam Physician 2011;84(6):690-2
   PubMed Web of Science ®Google Scholar
• Lapolla W, Digiorgio C, Haitz K, et al. Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. Arch Dermatol 2011;147(8):901-7
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep 2011;60(44):1528
   PubMedGoogle Scholar
• Takahashi M, Asano Y, Kamiya H, et al. Development of varicella vaccine. J Infect Dis 2008;197(Suppl 2):S41-4
   PubMedGoogle Scholar
• Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2(7892):1288-90
   PubMed Web of Science ®Google Scholar
• Takahashi M. A live varicella vaccine used for children in hospitals. IARC Sci Publ 1978(24 Pt 2):1033-6
   PubMedGoogle Scholar
• Baba K, Yabuuchi H, Okuni H, et al. Studies with live varicella vaccine and inactivated skin test antigen: protective effect of the vaccine and clinical application of the skin test. Pediatrics 1978;61(4):550-5
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;54(7):922-8
   PubMed Web of Science ®Google Scholar
• Gilderman LI, Lawless JF, Nolen TM, et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol 2008;15(2):314-19
   PubMed Web of Science ®Google Scholar
• Levin MJ, Oxman MN, Johnson GR, et al. Immune response to a refrigerator-stable zoster vaccine. Clin Vaccine Immunol 2009;16(9):1381; author reply -2
   PubMed Web of Science ®Google Scholar
• Merck. ZOSTAVAX Package Insert2012. Available from: http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf
   Google Scholar
• Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008;197(6):825-35
   PubMed Web of Science ®Google Scholar
• Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009;200(7):1068-77
   PubMed Web of Science ®Google Scholar
• Vermeulen JN, Lange JM, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults >/=60 years of age. Vaccine 2012;30(5):904-10
   PubMed Web of Science ®Google Scholar
• Vesikari T, Hardt R, Rumke HC, et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax (R)) in individuals aged >/=70 years: a randomized study of a single dose versus two different two-dose schedules. Hum Vaccin Immunother 2013;9(4):854-860
   Web of Science ®Google Scholar
• Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010;152(9):545-54
   PubMed Web of Science ®Google Scholar
• Murray AV, Reisinger KS, Kerzner B, et al. Safety and tolerability of zoster vaccine in adults >/=60 years old. Hum Vaccin 2011;7(11):1130-6
   PubMed Web of Science ®Google Scholar
• Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med 2013;10(4):e1001420
   PubMed Web of Science ®Google Scholar
• Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011;305(2):160-6
   PubMed Web of Science ®Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30; quiz CE2-4
   PubMedGoogle Scholar
• Sutradhar SC, Wang WW, Schlienger K, et al. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older. Clin Vaccine Immunol 2009;16(5):646-52
   PubMed Web of Science ®Google Scholar
• Tyring SK, Diaz-Mitoma F, Padget LG, et al. Safety and tolerability of a high-potency zoster vaccine in adults >/=50 or years of age. Vaccine 2007;25(10):1877-83
   PubMed Web of Science ®Google Scholar
• Arnou R, Fiquet A, Thomas S, et al. Immunogenicity and safety of ZOSTAVAX(R) approaching expiry potency in individuals aged >/=50 years. Hum Vaccin 2011;7(10):1060-5
   PubMed Web of Science ®Google Scholar
• Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine 2010;28(25):4204-9
   PubMed Web of Science ®Google Scholar
• MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults >/=60 years old. Hum Vaccin 2010;6(11):894-902
   PubMed Web of Science ®Google Scholar
• Tseng HF, Smith N, Sy LS, et al. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 2011;29(20):3628-32
   PubMed Web of Science ®Google Scholar
• Naidus E, Damon L, Schwartz BS, et al. Experience with use of zostavax(R) in patients with hematologic malignancy and hematopoietic cell transplant recipients. Am J Hematol 2012;87(1):123-5
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012;308(1):43-9
   PubMed Web of Science ®Google Scholar
• Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin 2010;6(4):318-21
   PubMed Web of Science ®Google Scholar
• Gershon AA, Levin MJ, Weinberg A, et al. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J 2009;28(7):653-5
   PubMed Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy. In ClinicalTrials.gov [Internet]. National Library of Medicine (US) 2000-[July 10, 2013]. Bethesda, MD. 2009. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT00851786?term=zostavax+hiv&rank=1; NLM: NCT00851786
   Google Scholar
• Merck & Co. ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017). In ClinicalTrials.gov [Internet]. National Library of Medicine (US) 2000- [July 10, 2013]. Bethesda, MD. 2011. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT00546819?term=zostavax+corticosteroids&rank=1&sect=X0125; NLM: NCT00546819
   Google Scholar
• Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992;166(5):1153-6
   PubMed Web of Science ®Google Scholar
• Glesby MJ, Moore RD, Chaisson RE. Herpes zoster in patients with advanced human immunodeficiency virus infection treated with zidovudine. Zidovudine Epidemiology Study Group. J Infect Dis 1993;168(5):1264-8
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Berger TG, Fikrig S, et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112(3):187-91
   PubMed Web of Science ®Google Scholar
• Vanhems P, Voisin L, Gayet-Ageron A, et al. The incidence of herpes zoster is less likely than other opportunistic infections to be reduced by highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005;38(1):111-13
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012;206(8):1280-90
   PubMed Web of Science ®Google Scholar
• Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics 2013;31(2):125-36
   PubMed Web of Science ®Google Scholar
• Reynolds MA, Kruszon-Moran D, Jumaan A, et al. Varicella seroprevalence in the U.S.: data from the National Health and Nutrition Examination Survey, 1999-2004. Public Health Rep 2010;125(6):860-9
   PubMed Web of Science ®Google Scholar
• Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003;70(Suppl 1):S111-18
   PubMedGoogle Scholar
• Garnett GP, Grenfell BT. The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiol Infect 1992;108(3):513-28
   PubMed Web of Science ®Google Scholar
• Garnett GP, Ferguson NM. Predicting the effect of varicella vaccine on subsequent cases of zoster and varicella. Rev Med Virol 1996;6(3):151-61
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ, Gay NJ, et al. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000;125(3):651-69
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Brisson M. The effect of vaccination on the epidemiology of varicella zoster virus. J Infect 2002;44(4):211-19
   PubMed Web of Science ®Google Scholar
• Karhunen M, Leino T, Salo H, et al. Modelling the impact of varicella vaccination on varicella and zoster. Epidemiol Infect 2010;138(4):469-81
   PubMed Web of Science ®Google Scholar
• Baxter R, Ray P, Tran TN, et al. Long-term effectiveness of varicella vaccine: a 14-year, prospective cohort study. Pediatrics 2013;131(5):e1389-96
   PubMed Web of Science ®Google Scholar
• Hicks LD, Cook-Norris RH, Mendoza N, et al. Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol 2008;144(5):603-8
   PubMed Web of Science ®Google Scholar
• Hernandez PO, Javed S, Mendoza N, et al. Family history and herpes zoster risk in the era of shingles vaccination. J Clin Virol 2011;52(4):344-8
   PubMed Web of Science ®Google Scholar
• Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007;25(49):8326-37
   PubMed Web of Science ®Google Scholar
• Bilcke J, Jan van Hoek A, Beutels P. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting? Hum Vaccin Immunother 2013;9:4
   Web of Science ®Google Scholar
• van Hoek AJ, Melegaro A, Gay N, et al. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine 2012;30(6):1225-34
   PubMed Web of Science ®Google Scholar